NASDAQ:MNOVMediciNova Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.44 -0.13 (-2.33 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$5.38Now: $5.44▼$5.6050-Day Range$4.97MA: $5.49▼$7.0652-Week Range$2.79Now: $5.44▼$10.84Volume67,131 shsAverage Volume141,211 shsMarket Capitalization$239.73 millionP/E RatioN/ADividend YieldN/ABeta1.71 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMediciNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, MediciNova has a potential upside of 102.2% from its current price of $5.44.Amount of Analyst CoverageMediciNova has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMediciNova has received 203 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMediciNova has received 176 “underperform” votes. (Add your “underperform” vote.)Community SentimentMediciNova has received 53.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote “Outperform” if you believe MNOV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have bought more of their company's stock than they have sold. Specifically, they have bought $69,240.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 15.30% of the stock of MediciNova is held by insiders.Percentage Held by InstitutionsOnly 21.80% of the stock of MediciNova is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.43) to ($0.51) per share.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNOV Previous Symbol CUSIPN/A CIK1226616 Webmedicinova.com Phone858-373-1500Debt Debt-to-Equity RatioN/A Current Ratio34.63 Quick Ratio34.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.71 per share Price / Book3.18Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-12,940,000.00 Net MarginsN/A Return on Equity-14.83% Return on Assets-14.07%Miscellaneous Employees9 Outstanding Shares44,068,000Market Cap$239.73 million Next Earnings Date7/23/2020 (Estimated) OptionableOptionable NASDAQ:MNOV Rates by TradingView Receive MNOV News and Ratings via Email Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. MediciNova (NASDAQ:MNOV) Frequently Asked Questions How has MediciNova's stock been impacted by COVID-19 (Coronavirus)? MediciNova's stock was trading at $3.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MNOV shares have increased by 65.3% and is now trading at $5.44. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of MediciNova? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MediciNova. When is MediciNova's next earnings date? MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for MediciNova. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Thursday, April, 23rd. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.02. View MediciNova's earnings history. What price target have analysts set for MNOV? 1 equities research analysts have issued 1-year price targets for MediciNova's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate MediciNova's share price to reach $11.00 in the next year. This suggests a possible upside of 102.2% from the stock's current price. View analysts' price targets for MediciNova. Has MediciNova been receiving favorable news coverage? Press coverage about MNOV stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MediciNova earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMediciNova. Are investors shorting MediciNova? MediciNova saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,260,000 shares, a drop of 6.2% from the April 30th total of 2,410,000 shares. Based on an average trading volume of 180,800 shares, the short-interest ratio is currently 12.5 days. Currently, 6.1% of the company's shares are sold short. View MediciNova's Current Options Chain. Who are some of MediciNova's key competitors? Some companies that are related to MediciNova include Athenex (ATNX), BioXcel Therapeutics (BTAI), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), Passage Bio (ORIC), ImmunoGen (IMGN), Stoke Therapeutics (STOK), Cue Biopharma (CUE), Endo International (ENDP), NextCure (NXTC), Omeros (OMER), Arcturus Therapeutics (ARCT), Gossamer Bio (GOSS), Kura Oncology (KURA) and Kala Pharmaceuticals (KALA). View all competitors. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), Geron (GERN), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Catalyst Pharmaceuticals (CPRX). Who are MediciNova's key executives? MediciNova's management team includes the following people: Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)Ms. Carla Reyes, Chief Financial Officer (Age 47)Mr. John O'Neil CPA, Controller What is MediciNova's stock symbol? MediciNova trades on the NASDAQ under the ticker symbol "MNOV." Who are MediciNova's major shareholders? MediciNova's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.42%), Essex Woodlands Management Inc. (2.51%), State Street Corp (1.69%), Geode Capital Management LLC (1.28%), Morgan Stanley (0.52%) and Alps Advisors Inc. (0.18%). Company insiders that own MediciNova stock include Kazuko Matsuda and Yuichi Iwaki. View institutional ownership trends for MediciNova. Which institutional investors are selling MediciNova stock? MNOV stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, State Street Corp, Essex Woodlands Management Inc., Alps Advisors Inc., BlackRock Inc., and Deutsche Bank AG. View insider buying and selling activity for MediciNova. Which institutional investors are buying MediciNova stock? MNOV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Geode Capital Management LLC, JPMorgan Chase & Co., SG Americas Securities LLC, BNP Paribas Arbitrage SA, Jane Street Group LLC, and Citigroup Inc.. Company insiders that have bought MediciNova stock in the last two years include Kazuko Matsuda, and Yuichi Iwaki. View insider buying and selling activity for MediciNova. How do I buy shares of MediciNova? Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MediciNova's stock price today? One share of MNOV stock can currently be purchased for approximately $5.44. How big of a company is MediciNova? MediciNova has a market capitalization of $239.73 million. MediciNova employs 9 workers across the globe. What is MediciNova's official website? The official website for MediciNova is medicinova.com. How can I contact MediciNova? MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
